TR200003736T2 - Anksiyete durumlarına ya da depresyona bağlı değişikliklerin önlenmesi - Google Patents

Anksiyete durumlarına ya da depresyona bağlı değişikliklerin önlenmesi

Info

Publication number
TR200003736T2
TR200003736T2 TR2000/03736T TR200003736T TR200003736T2 TR 200003736 T2 TR200003736 T2 TR 200003736T2 TR 2000/03736 T TR2000/03736 T TR 2000/03736T TR 200003736 T TR200003736 T TR 200003736T TR 200003736 T2 TR200003736 T2 TR 200003736T2
Authority
TR
Turkey
Prior art keywords
depression
prevention
changes due
anxiety states
anxiety
Prior art date
Application number
TR2000/03736T
Other languages
English (en)
Inventor
Cavazza Claudio
Original Assignee
Sigma-Tau Healthscience S.P.A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma-Tau Healthscience S.P.A filed Critical Sigma-Tau Healthscience S.P.A
Publication of TR200003736T2 publication Critical patent/TR200003736T2/tr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/38Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Bu bulusta, anksiyete durumlarina ya da depresyona bagli sinirsel ve davranissal degisikliklerin önlenmesi ve/ ya da tedavisi için nöroprotektif bilesim tarif edilmektedir ki söz konusu bilesim bir besin destegi, diyet takviyesi ya da karakterize edici aktif madde olarak aseyil L-karnitin ve hipersin ihtiva eden bir ilaç halinde olabilir.
TR2000/03736T 1998-06-25 1999-06-17 Anksiyete durumlarına ya da depresyona bağlı değişikliklerin önlenmesi TR200003736T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT98RM000425A IT1299195B1 (it) 1998-06-25 1998-06-25 Composizione ad attivita' neuroprotettiva per la prevenzione ed il trattamento delle alterazioni nervose e comportamentali legate a stati

Publications (1)

Publication Number Publication Date
TR200003736T2 true TR200003736T2 (tr) 2001-06-21

Family

ID=11406010

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/03736T TR200003736T2 (tr) 1998-06-25 1999-06-17 Anksiyete durumlarına ya da depresyona bağlı değişikliklerin önlenmesi

Country Status (26)

Country Link
US (1) US6346282B1 (tr)
EP (1) EP1089744B1 (tr)
JP (1) JP2002518438A (tr)
KR (1) KR20010053059A (tr)
CN (1) CN1307479A (tr)
AT (1) ATE228369T1 (tr)
AU (1) AU756542B2 (tr)
BR (1) BR9912179A (tr)
CA (1) CA2334858C (tr)
DE (1) DE69904173T2 (tr)
DK (1) DK1089744T3 (tr)
EE (1) EE200000729A (tr)
ES (1) ES2188178T3 (tr)
HU (1) HUP0102546A3 (tr)
IL (1) IL140159A0 (tr)
IS (1) IS5765A (tr)
IT (1) IT1299195B1 (tr)
MA (1) MA26651A1 (tr)
NO (1) NO20006430L (tr)
NZ (1) NZ508882A (tr)
PL (1) PL194177B1 (tr)
PT (1) PT1089744E (tr)
SK (1) SK19302000A3 (tr)
TN (1) TNSN99135A1 (tr)
TR (1) TR200003736T2 (tr)
WO (1) WO1999066914A2 (tr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6348495B1 (en) * 1996-06-06 2002-02-19 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Method for treating celiac disease
DE10015617A1 (de) * 2000-03-29 2001-10-04 Peter Laetzsch Migränemittel
US7208180B2 (en) * 2000-05-08 2007-04-24 N.V. Nutricia Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith
US7226916B1 (en) 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
IT1317035B1 (it) * 2000-05-30 2003-05-26 Sigma Tau Healthscience Spa Integratore ad attivita' antiossidante comprendente unaalcanoilcarnitina ed una associazione di polifenoli estratti dal
US7407778B2 (en) * 2002-02-07 2008-08-05 Pettegrew Jay W Compounds, compositions and methods for treating neuropsychiatric disorders
US7700074B2 (en) * 2002-02-07 2010-04-20 Pettegrew Jay W Method and system for diagnosis of neuropsychiatric disorders including chronic alcoholism
DE10213571A1 (de) * 2002-03-26 2003-10-23 Lichtwer Pharma Ag Pflanzenextrakte und deren Anwendung
US7674482B2 (en) * 2002-08-27 2010-03-09 Targeted Medical Pharma Inc. Method and compositions for potentiating pharmaceuticals with amino acid based medical foods
US20040067986A1 (en) * 2002-10-04 2004-04-08 Nathan Sassover Neuro-degenerative inhibitor, neuro-endocrine modulator, and neuro-cerebral metabolism enhancer
US20060257842A1 (en) * 2003-05-29 2006-11-16 Pettegrew Jay W Cryopreservation media and molecules
WO2004110963A2 (en) * 2003-05-29 2004-12-23 Pettegrew Jay W Glycerophosphocholine and its derivatives for medical imaging neuropsychiatric disorders
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
US20070065486A1 (en) * 2004-05-21 2007-03-22 Migco Limited Migraine remedy
US20060115555A1 (en) * 2004-12-01 2006-06-01 Foulger Sidney W Nutritional supplements containing xanthone extracts
US20060115556A1 (en) * 2004-12-01 2006-06-01 Foulger Sidney W Nutritional supplement drink containing xanthone extracts
EP1854486A3 (de) * 2006-03-14 2010-06-02 Wilfried P. Bieger Verwendung von Neurotransmitter-Derivaten zur Herstellung von Mitteln zur Behandlung von neuroendokrinen gesundheitlichen Störungen
US8461389B2 (en) 2008-04-18 2013-06-11 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
US20110217252A1 (en) * 2008-11-11 2011-09-08 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Compound useful for treating cellulite
BRPI0900614A2 (pt) 2009-02-13 2011-06-28 Univ Fed Do Rio Grande Do Sul Ufrgs extrato vegetal neuroativo, composição farmacêutica compreendendo o mesmo e processo para sua produção
PT2582368T (pt) * 2010-06-16 2018-06-04 Alfasigma Spa Acetil-carnitina, para utilização num método para o aumento da neurogénese em tecido neuronal
US20150141380A1 (en) 2010-08-05 2015-05-21 Case Western Reserve University Inhibitors of erk for developmental disorders of neuronal connectivity
JP2014145857A (ja) 2013-01-28 2014-08-14 Sony Corp 表示装置およびその製造方法、並びに電子機器
WO2016126169A1 (ru) * 2015-02-04 2016-08-11 Общество С Ограниченной Ответственностью "Консорциум-Пик" Способ повышения эффективности терапии антидепрессантом в комплексной антидепрессивной терапии и фармацевтическая комбинация

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4346107A (en) * 1979-02-12 1982-08-24 Claudio Cavazza Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism
DE4239959A1 (de) * 1992-11-27 1994-06-01 Schwabe Willmar Gmbh & Co Johanniskraut-Trockenextrakt, Verfahren zu seiner Herstellung und seine Verwendung
IT1276225B1 (it) * 1995-10-17 1997-10-27 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche contenenti l-carnitina e alcanoil l- carnitine in associazione con resveratrolo o suoi derivati utili per
US5911992A (en) * 1997-06-12 1999-06-15 A. Glenn Braswell Method for controlling weight with hypericum perforatum and garcinia cambogia

Also Published As

Publication number Publication date
NO20006430L (no) 2001-02-21
CN1307479A (zh) 2001-08-08
US6346282B1 (en) 2002-02-12
IS5765A (is) 2000-12-08
PL345279A1 (en) 2001-12-03
ATE228369T1 (de) 2002-12-15
DE69904173D1 (de) 2003-01-09
IL140159A0 (en) 2002-02-10
SK19302000A3 (sk) 2001-09-11
BR9912179A (pt) 2001-04-10
TNSN99135A1 (fr) 2005-11-10
DE69904173T2 (de) 2003-08-28
AU756542B2 (en) 2003-01-16
EE200000729A (et) 2002-06-17
HUP0102546A2 (hu) 2001-10-28
DK1089744T3 (da) 2003-03-24
PL194177B1 (pl) 2007-05-31
ITRM980425A1 (it) 1999-12-25
AU4391099A (en) 2000-01-10
KR20010053059A (ko) 2001-06-25
EP1089744A2 (en) 2001-04-11
JP2002518438A (ja) 2002-06-25
WO1999066914A3 (en) 2000-04-06
IT1299195B1 (it) 2000-02-29
WO1999066914A2 (en) 1999-12-29
CA2334858C (en) 2010-08-24
NZ508882A (en) 2002-06-28
PT1089744E (pt) 2003-04-30
HUP0102546A3 (en) 2003-08-28
ES2188178T3 (es) 2003-06-16
MA26651A1 (fr) 2004-12-20
ITRM980425A0 (it) 1998-06-25
CA2334858A1 (en) 1999-12-29
NO20006430D0 (no) 2000-12-15
EP1089744B1 (en) 2002-11-27

Similar Documents

Publication Publication Date Title
TR200003736T2 (tr) Anksiyete durumlarına ya da depresyona bağlı değişikliklerin önlenmesi
TR200100610T2 (tr) Asetil L-karnitin ve alfa-lipoik asit içeren antioksidant bileşim
TR200003735T2 (tr) Osteoporoz ve menopoz sendromuna bağlı rahatsızlıkların önlenmesi ve tedavileri
BR9711126A (pt) Medicamentos antiestresse e alimentos funcionais com efeitos antiestresse.
BRPI0405301A (pt) Sistema para a liberação de um ou mais ingredientes ativos de uma composição, produtos para cuidado pessoal para pele e cabelos, para cuidado de tecido, e doméstico, e, processo para a preparação de um sistema para a liberaçao de um ou mais ingredientes ativos de uma composição
ATE361084T1 (de) Topische pharmazeutische zusammensetzungen mit proanthocyanidinen, glycyrrhetinic säure und telmesteine zur behandlung von dermatitis
ATE253351T1 (de) Desodoriende zubereitungen enthaltend wasserlösliche -(1,3)-glucane
PL373465A1 (en) Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives
DE60229431D1 (de) Verwendungen von chitosanoligosacchariden
ATE291424T1 (de) Katechin und quercetin zur pharmazeutischen oder diätetischen verwendung
DE60108325D1 (de) Pharmazeutische oder diätetische zusammensetzungen aus pilzen und deren verwendung
DE69925824D1 (de) Glutathionderivate und dazugehörige dosisformen
IS2742B (is) Samsetning@sem@nær@yfir@basískan@svingómýelínasa@af@bakteríuuppruna@til@nota@sem@næringarfræðileg@efnablanda@@fæðubótarefni@eða@lyfjaafurð
DE60117606D1 (de) Orale zusammensetzungen zur behandlung von kopfhauterkrankungen
TR200200948T2 (tr) L-karnitin türevlerini ve ginkgo biloba özlerini içeren bileşim
KR970032795A (ko) 요산 및 요산 분해 효소의 유효 함량을 함유하는 화장용 및 피부 관리용 조성물
RS50148B (sr) Upotreba docetaksela za lečenje hepatoćelijskog karcinoma
TR200100637T2 (tr) Yeni doğal ürün türevleri
TR200003737T1 (tr) Diyet takviyesi ya da ilaç olarak kullanılan bileşim
BR0307696A (pt) Composição desodorante ou antitranspirante
TNSN99138A1 (fr) Une composition antioxydante, cytostatique et a support energetique qui ameliore l'utilisation metabolique du glucose
TR200101344T2 (tr) Propionil L-karnitinden ve bir flavonoid'den oluşan antioksidan bileşim
DE69927260D1 (de) Topische pharmazeutische zusammensetzung zur behandlung von haut- oder zirkulatorischen krankheiten auf inflammatorischer, immun-, proliferativer oder degenerativer basis
BR0108405A (pt) Agente de ativação de célula
DE60002607D1 (de) Zusammensetzung zur vorbeugung und/oder behandlung von störungen aufgrund von abnormalen fettstoffmetabolismus, enthaltend l-carnitin und chitosan